An interventional study of HeartHome in Myocardial Infarction, Acute Coronary Syndrome and ST-segment Elevation Myocardial Infarction (STEMI), sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-04-04.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Supportive care
The purpose of this implementation trial is to execute a nurse-led, home-based cardiac rehabilitation (HBCR) program, evaluate the program's impact on patient outcomes over 6 months; and compare outcomes of HeartHome (HH) participants to a group of participants in traditional cardiac rehabilitation (CR).
Despite being recognized as a class 1 recommendation by the American Heart Association (AHA), traditional CR is underused: only 20% of patients who need CR are referred, and only half of those referred enroll in the program. The primary barriers to enrollment in CR include the failure of providers to refer patients; systems that lack a clear, streamlined referral process; and patients who face multiple barriers, including knowledge, transportation, cost, time, and social-family support.
The HeartHome program is adapted from MULTIFIT, an evidence-based, interdisciplinary model of care developed at Stanford University was originally designed to provide coronary risk factor modification in post-MI patients, and later modified to implement consensus guidelines for providing HBCR to individuals with CVD using nurse managed care via telephone follow-up. HeartHome will combine nurse home visits with telephone and electronic supports for participants in a HBCR program that allows them to engage in cardiac rehabilitation programs at home.
In this trial, nurses will deliver the 12-week educational program to 150 participants. Participants will then complete follow-up assessments at the end of the program (3 months post enrollment), and then at 6-months post enrollment. The data collected will be compared to a control group that contains de-identified data from 150 patients that attend the traditional cardiac rehab program.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 14 is below the median of 148 across 1,595 interventional studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →University of North Carolina, Chapel Hill is the lead sponsor of 1,340 studies on the registry; 133 are open to participants now.
Of its 155 completed or terminated interventional studies of FDA-regulated products, 136 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Individuals are eligible for the HeartHome study if they meet all the following inclusion criteria:
Individuals are not eligible for the HeartHome study if they meet any of the following exclusion criteria:
Participants will be in the HeartHome program for a total of 12 weeks.
Behavioral: HeartHome
De-identified data from 150 patients who attend a traditional cardiac rehabilitation program during the same general time of the HeartHome implementation
The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
Number of HeartHome patient referrals into the HeartHome program
Number of patient referrals into the HeartHome program will be measured by the total number of participants eligible to enroll in traditional cardiac rehab that were referred to the HeartHome program.
Time frame: 10 months after beginning of study
Proportion of HeartHome patient referral into the HeartHome program
Proportion of patient referrals into the HeartHome program will be measured by the number of patients referred to the HeartHome program relative to the number of patients referred to traditional cardiac rehab.
Time frame: 10 months after beginning of study
Proportion of HeartHome patient enrollments in the HeartHome program
Proportion of patient enrollments in the HeartHome program will be measured by the number of patients who enroll in the HeartHome program relative to the number of eligible patients referred to the HeartHome program. Enrollment is defined by signing the study consent form.
Time frame: 10 months after beginning of study
Participation in HeartHome's participants in-person visits
Participation in HeartHome's in-person visits will be measured by the number of in-person visits that each participant attends relative to the total number of in-person visits. The total number of visits possible per person is 5, with higher numbers associated with better participation.
Time frame: 12 weeks post HeartHome intervention start
Participation in HeartHome's participants interactive online classes
Participation in HeartHome's online classes will be measured by the number of online classes that each participant attends relative to the total number of interactive online classes. The total number of classes possible is 7, with higher numbers associated with better participation.
Time frame: 12 weeks post HeartHome intervention start
Participation in HeartHome intervention calls
Participation in HeartHome's calls will be measured by the number of calls that each participant attends relative to the total number of calls. The total number of calls possible is 8, with higher rate associated with better participation.
Time frame: 12 weeks post HeartHome intervention start
HeartHome intervention weekly goal adherence score
Adherence to weekly goals will be measured by participant goal achievement, which includes 33 opportunities for goal achievement and progression. The range is 0-33, with higher scores associated with greater adherence to weekly goals.
Time frame: 12 weeks post HeartHome intervention start
Number of sessions completed.
Sessions completed by participants will be measured by the total number of calls, interactive online classes, and in-person visits attended. The total number of sessions is 20, with higher numbers associated with higher participation. Sessions completed by the control group will be measured by the total number of exercise sessions and classes attended. The total number of sessions for the control group is 46, with higher numbers associated with higher participation.
Time frame: 13-weeks post start of HeartHome and control intervention
HeartHome participants' physical function at baseline and at week 12
HeartHome participants' physical function will be measured by the six-minute walk distances at baseline and at 12 weeks. Longer distances (in meters) are associated with higher physical function.
Time frame: 12 weeks post start of HeartHome intervention
Change in HeartHome participant's physical functioning, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' physical function will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better physical function.
Time frame: 12- and 24-weeks post start of intervention
Change in HeartHome participant's role limitations due to physical health, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' role limitations due to physical health will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with fewer role limitations due to physical health.
Time frame: 12- and 24- weeks post start of intervention
Change in HeartHome participant's role limitations due to emotional problems, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' role limitations due to emotional problems will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with fewer role limitations due to emotional problems.
Time frame: 12- and 24- weeks post start of intervention
Change in HeartHome participant's energy/fatigue, sub score of RAND SF-36 from baseline to week 12 and baseline to week 24.
Change in participants' energy/fatigue will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with higher energy/lower fatigue.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's emotional well-being, sub score of RAND SF-36, assessed at baseline, week 12, and week 24.
Participants' emotional well-being will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better emotional well-being.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's social functioning, sub score of RAND SF-36, evaluated at baseline, week 12, and week 24.
Participants' social functioning will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better social functioning.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's bodily pain, a sub score of RAND SF-36, will be evaluated at baseline, week 12 and week 24.
Participants' bodily pain will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with less pain.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's general health, sub score of RAND SF-36 at baseline, week 12, and week 24.
Participants' general health will be measured by a sub score of the RAND Short Form Survey Instrument (SF-36). The range is 0 - 100, and higher scores are associated with better general health.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's change of participant and control physical functioning, sub score of RAND SF-36, from baseline to week 12 to end of program
Participants' physical function will be measured by a sub score of the RAND SF-36. The range is 0-100, and higher scores are associated with better physical functioning.
Time frame: 13-weeks post start of HeartHome and control intervention
HeartHome participant's blood pressure at baseline and weeks 3, 5, 7 and 12.
Blood pressure will be measured by blood pressure measurements, measured in mmHg.
Time frame: Baseline, weeks 3, 5, 7, and 12 of intervention
Participants' and control's blood pressure at baseline and 12 weeks
Blood pressure will be measured by blood pressure measurements, measured in mmHg.
Time frame: Baseline and 13-weeks post start of HeartHome and control intervention
Change in HeartHome participant's reported nicotine use from baseline to week 12 and baseline to week 24.
Rates of nicotine use will be measured by the change in participant-reported number of cigarettes smoked per week and patient-report of weekly frequency of non-cigarette nicotine use from baseline to week 12, and baseline to week 24.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's waist circumference from baseline to week 12.
Waist circumference will be measured in centimeters at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Negative changes in waist circumference are associated with greater weight loss.
Time frame: 12 weeks post start of intervention
HeartHome participant's Body Mass Index at baseline and week 12.
Body Mass Index will be calculated from the participants' weights and heights at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Lower numbers are associated with weight loss, and a patients' healthy range varies by age and gender.
Time frame: Baseline and 12 weeks post start of intervention
Change of HeartHome participants' and control Body Mass Index from baseline to week 12
Body Mass Index will be calculated by assessing participant weight and height at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome Program). Lower numbers are associated with weight loss, and a patients' healthy range varies by age and gender.
Time frame: Baseline and 13-weeks post start of HeartHome and control intervention
HeartHome participant's average weekly steps walked from baseline to week 12.
Average steps walked will be calculated using electronic fitness trackers at the beginning of the intervention (HeartHome program) and 12 weeks after beginning the intervention (HeartHome program). Higher numbers are associated with higher physical activity.
Time frame: 12 weeks post start of intervention
HeartHome participant's self-Reported and medical record reviewed number of hospital admissions 12 and 24 weeks after beginning of heart home program.
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of instances the participant is hospitalized in 12 and 24 weeks after the beginning of the heart home program.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's self-Reported and medical record reviewed number of days hospitalized 12 and 24 weeks after beginning of heart home program.
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of combined days the participant spends in the hospital in 12 and 24 weeks after the beginning of the heart home program.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant and control number of hospital readmissions at 12 weeks
Hospital readmission will be measured using patient self-reports and medical record reviews of hospital admissions (yes/no) at 12 weeks after the start of the intervention (HeartHome program).
Time frame: 13-weeks post start of HeartHome and control intervention
HeartHome participant's self-reported and medical record reviewed number of ED visits without hospital admissions 12 and 24 weeks after beginning of HeartHome program
Participants' days of care utilization will be measured using the self-reported and medical record reviewed number of combined visits the participant makes to the Emergency Department (ED) in 12 and 24 weeks after the beginning of the heart home program.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's self-reported and medical record reviewed number of specialist visits 12 and 24 weeks after beginning of the HeartHome program
Participants' number of specialist visits will be measured using self-reported and medical record reviewed number of combined cardiology visits 12 and 24 weeks after the beginning of the heart home program.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's self-reported and medical record reviewed number of primary care visits 12 and 24 weeks after beginning of the HeartHome program
Participants' number of primary care visits will be measured using self-reported and medical record reviewed number of combined primary care visits 12 and 24 weeks after the beginning of the heart home program.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's self-reported and medical record reviewed number of urgent care visits 12 and 24 weeks after beginning of the HeartHome program
Participants' number of urgent care visits will be measured using self-reported and medical record reviewed number of combined urgent care visits 12 and 24 weeks after the beginning of the heart home program.
Time frame: 12- and 24- weeks post start of intervention
HeartHome participant's Morisky 4-Item Scale scores at baseline, week 12, and week 24.
Management of participants' medications will be measured using the Morisky 4-item scale, which includes four questions to estimate the risk of medication non-adherence. The range is 0 to 4, and lower scores are associated with lower levels of medication adherence.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's change in perceived stress scale from baseline to week 12 and baseline to week 24.
Participants' stress and emotional state will be measured using the perceived stress scale, which includes ten questions about individuals' feelings and thoughts during the last month. The range is 0-40, and higher scores are associated with higher levels of perceived stress.
Time frame: 12 and 24 weeks post start of intervention
HeartHome participant's change in dietary risk assessment from baseline to week 12 and baseline to week 24.
Participants' diet and lifestyle change will be measured by the dietary risk assessment, which includes 33 questions about how many servings of commonly eaten foods that participants eat in a usual day or an average week. The range is 0-52, higher scores represent a more healthful dietary pattern.
Time frame: 12- and 24- weeks post start of intervention
Participants' and control's dietary risk assessment scores from baseline to week 12 to dietary risk assessment scores of control group.
Participants' diet and lifestyle change will be measured by the dietary risk assessment, which includes 33 questions about how many servings of commonly eaten foods that participants eat in a usual day or an average week. The range is 0-52, higher scores represent a more healthful dietary pattern.
Time frame: 13-weeks post start of HeartHome and control intervention
HeartHome participant's change in PHQ-9 from baseline to week 12.
Participants' emotional state will be measured by the Patient Health Questionnaire (PHQ)-9, which includes 9 questions for screening, diagnosing, monitoring, and measuring the severity of depression. The range is 0 to 27, and scores represent cut-points for mild to severe levels of depression.
Time frame: 12 weeks post start of intervention
Change in participants' and control's PHQ-9 from baseline to week 12.
Participants' emotional state will be measured by the PHQ-9, which includes 9 questions for screening, diagnosing, monitoring, and measuring the severity of depression. The range is 0 to 27, and scores represent cut-points for mild to severe levels of depression, with higher scores associated with more severe levels of depression.
Time frame: 13-weeks post start of HeartHome and control intervention
HeartHome participant's change in New General Self-Efficacy score from baseline to week 12 and baseline to week 24.
Participants' confidence regarding task and situational performance is measured by the New General Self-Efficacy Scale, which includes 8 questions about participant confidence. The range is 8 to 40, and higher scores are associated with higher self-efficacy.
Time frame: 12- and 24-weeks post start of intervention
HeartHome participant's change in knowledge of cardiac rehabilitation from baseline to 12 weeks and baseline to 24 weeks.
Participants' knowledge of cardiac rehabilitation is measured by a 10-item Cardiac Rehabilitation Knowledge test at baseline, 12 weeks and 24 weeks. Scores range from 0-10, with higher scores associated with greater knowledge of cardiac rehabilitation.
Time frame: 12- and 24-weeks post start of intervention
Participants' and control's change in knowledge of cardiac rehabilitation from baseline to 12 weeks.
Participants' knowledge of cardiac rehabilitation is measured by a 10-item Cardiac Rehabilitation Knowledge test at baseline, 12 weeks and 24 weeks. Scores range from 0-10, with higher scores associated with greater knowledge of cardiac rehabilitation.
Time frame: 13-weeks post start of HeartHome and control intervention
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill